Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$76.50 USD
+0.55 (0.72%)
Updated Nov 4, 2025 03:59 PM ET
After-Market: $76.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Protagonist Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
PTGX 76.50 +0.55(0.72%)
Will PTGX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.

Other News for PTGX
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Perspective Therapeutics (CATX)
1,2,3 Pullback Bullish appears for PTGX after 3.4% move
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
PTGX's price rises by 0.99% on October 31, though its technical setup remains stable.
Technical picture remains unchanged for PTGX after it rises 1.51% on October 30